Report #2897531

Received May 22, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 63 yrs
State: SC
Recovered: Unknown
Vaccinated: May 17, 2026
Onset: May 17, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
MMR	MEASLES + MUMPS + RUBELLA (PRIORIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	4N222	IM

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Intramuscular administration.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 63-year-old male patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On 17-MAY-2026, the patient received Priorix (intramuscular). On 17-MAY-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Intramuscular administration.). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 18-MAY-2026 The Priorix was administered intramuscularly instead of subcutaneous.